| Name | Title | Contact Details |
|---|
Community Blood Ctr is a Saint Joseph, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Absorption Systems is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Exton, PA. To find more information about Absorption Systems, please visit www.absorption.com
For over 25 years, Guaranteed Returns has provided pharmaceutical return services to hospital, government, independent retail, chain-store, LTC, Mail-Order and clinic pharmacies. Local GRx on-site service representatives are highly valued by customers for their professionalism, trustworthiness and for “going above and beyond”. Guaranteed Returns puts their longevity and industry knowledge to work to obtain the maximum amount of credits for every pharmacy return. GRx concentrates on providing pharmaceutical return solutions that address all aspects of the business, beginning with the manufacturer, through crediting the customer. Business review consultations, inventory management assistance and an unbeatable customer service department are just a few of the attributes that customers say sets GRx apart. Their flagship program, ReverseLink One™ has been branded as “the most cost effective return goods program ever to be offered by any 3rd party returns company”. Guaranteed Returns is dedicated to making pharmaceutical returns as simple as possible for customers while attaining the maximum amount of credits. Guaranteed Returns puts their 25 years of knowledge to work every day – continually investing in new programs, technologies and people - which is why GRx delivers Service You Can Count On.
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.